Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 105,895 | -56,418 | -55,193 | 872,132 | -199,426 |
| Depreciation Amortization | -1,204 | -799 | 104 | 3,035 | 4,812 |
| Income taxes - deferred | -11,519 | -7,573 | 3,207 | N/A | N/A |
| Accounts payable and accrued liabilities | 326 | 750 | 6 | -1,612 | -3,534 |
| Other Working Capital | 120,471 | 20,355 | -8,340 | 42,350 | -39,549 |
| Other Operating Activity | 24,572 | 32,150 | 33,219 | -1,102,896 | 29,839 |
| Operating Cash Flow | $238,541 | $-11,535 | $-26,997 | $-186,991 | $-207,858 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 0 | 15,838 | 71,377 | 17 | N/A |
| PPE Investments | -42 | -332 | -975 | 1,294 | -3,400 |
| Net Acquisitions | N/A | N/A | N/A | 2,709 | N/A |
| Purchase Of Investment | -248,217 | -140,743 | -134,534 | -103,145 | -158,305 |
| Sale Of Investment | 142,975 | 139,813 | 31,435 | 158,000 | 286,199 |
| Other Investing Activity | 0 | -2,292 | 0 | 1,095,134 | 0 |
| Investing Cash Flow | $-105,284 | $12,284 | $-32,697 | $1,154,009 | $124,494 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -631,603 | -10,730 |
| Common Stock Issued | 786 | 607 | 618 | 802 | 111,651 |
| Common Stock Repurchased | -4,034 | -3,104 | -199,551 | -132,280 | -9,061 |
| Other Financing Activity | 0 | 0 | 0 | 4,275 | 0 |
| Financing Cash Flow | $-3,248 | $-2,497 | $-198,933 | $-758,806 | $91,860 |
| Beginning Cash Position | 38,633 | 40,381 | 299,008 | 90,796 | 82,300 |
| End Cash Position | 168,642 | 38,633 | 40,381 | 299,008 | 90,796 |
| Net Cash Flow | $130,009 | $-1,748 | $-258,627 | $208,212 | $8,496 |
| Free Cash Flow | |||||
| Operating Cash Flow | 238,541 | -11,535 | -26,997 | -186,991 | -207,858 |
| Capital Expenditure | -42 | -332 | -2,488 | -572 | -3,406 |
| Free Cash Flow | 238,499 | -11,867 | -29,485 | -187,563 | -211,264 |